Filing Details
- Accession Number:
- 0001179110-20-008799
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-07 17:04:18
- Reporting Period:
- 2020-08-05
- Accepted Time:
- 2020-08-07 17:04:18
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1379970 | C Steven Gilman | C/O Momenta Pharmaceuticals, Inc 301 Binney Street Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-08-05 | 13,000 | $10.63 | 20,796 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-08-05 | 13,000 | $32.75 | 7,796 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-05 | 13,000 | $0.00 | 13,000 | $10.63 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2019-06-22 | 2026-06-22 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 trading plan dated May 22, 2020
- This transaction was executed in multiple trades at prices ranging from $32.27 to $32.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.